Economic evaluation of robot-assisted laparoscopic radical prostatectomy vs conventional laparoscopic radical prostatectomy and open retropubic radical prostatectomy in prostate cancer: a real-life study based on the French National Healthcare Data System (SNDS). (ECOREPAR)

29/01/2020
11/08/2026
EU PAS number:
EUPAS33290
Study
Finalised
Study type

Study topic

Medical procedure

Study type

Non-interventional study

Scope of the study

Effectiveness study (incl. comparative)

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medical condition to be studied

Prostate cancer
Population studied

Short description of the study population

Men undergoing surgery for prostate cancer between 2012 and 2015.

Age groups

  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)

Estimated number of subjects

10400
Study design details

Study design

Economic evaluation/ cost-effectiveness evaluation

Main study objective

The main objective is to assess thereal-life incremental cost-effectiveness ratio at 5 years, of the robot-assisted laparoscopic radical prostatectomy compared with laparoscopic radical prostatectomy and open retropubic radical prostatectomy in the the French National Claims Database (SNDS).

Setting

French nationwide claims database

Comparators

Open radical prostatectomy (ORP).

Outcomes

Incremental cost / progression-free (without additional treatment) life-year saved 5 years after initial surgery, 1)Incremental cost / life-year saved at 8 years. 2)Cost of robotic surgery.3)Outcomes measured at 5 and 8 years: Overall survival, Disease progression requiring a new treatment for prostate cancer,Continence disorders requiring treatment,Erectile dysfunction requiring treatment,Total healthcare consumptions.4)Urological hospitalizations within 90 days following the initial surgery.

Data analysis plan

Following analyses will be done:1) Conditional probability of benefiting from the three surgical procedures using the high-dimensional propensity score (hdPS). Subjects from each group will be 1:1 matched on the score value.2) Progression-free survival at 5 and 8 years using Kaplan-Meier method. 3) Comparison of events rates between groups using proportional Cox models in total population with/without adjustment on hdPS, and in hdPS-matched populations. 4) None-adjusted estimation of cost-effectiveness ratios (95% CI estimated by boostrap).5) Net Monetary Benefit estimation of each surgical procedure (NMB = E x λ – C) with λ = differential cost-effectiveness threshold.6) hdPS-adjusted analysis using simple linear regression model, with BNM as dependent variable and type of surgery and hdPS as independent variables: one model to compare robot-assisted procedure with open procedure, and another to compare robot-assisted procedure with laparoscopic procedure.

Summary results

5,677 men could be matched with a median follow-up of 6.7 years. PFS and OS were longer with RARP compared to ORP (HR = 0.85 [95%CI: 0.79-0.91, p < 0.001] and 0.79 [0.68-0.92, p = 0.003], respectively). Index hospitalisation duration was shorter for RARP (6.7 ± 4.0 days vs. 9.9 ± 5.0 days, p < 0.01). At follow-up, care for urinary incontinence and erectile dysfunction were less frequent with RARP (29.7% vs. 37.3%; p < 0.01 and 52.1% vs. 56.3%; p < 0.01, respectively). Results were similar with all patients after IPTW adjustment except no difference for erectile dysfunction care.